Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Down 33.8% in December

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the target of a large decrease in short interest in December. As of December 15th, there was short interest totalling 91,700 shares, a decrease of 33.8% from the November 30th total of 138,600 shares. Based on an average trading volume of 2,921,900 shares, the days-to-cover ratio is currently 0.0 days.

Bayer Aktiengesellschaft Stock Up 2.5 %

BAYRY opened at $4.97 on Friday. Bayer Aktiengesellschaft has a twelve month low of $4.79 and a twelve month high of $9.79. The company has a quick ratio of 0.81, a current ratio of 1.32 and a debt-to-equity ratio of 1.19. The firm has a 50 day moving average price of $5.66 and a 200-day moving average price of $6.85. The stock has a market capitalization of $19.53 billion, a price-to-earnings ratio of -19.12 and a beta of 1.03.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its quarterly earnings results on Tuesday, November 12th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.10). Bayer Aktiengesellschaft had a negative net margin of 2.02% and a positive return on equity of 16.90%. The firm had revenue of $10.96 billion for the quarter. Equities research analysts forecast that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Bank of America upgraded Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research note on Friday, September 6th. Five analysts have rated the stock with a hold rating, According to MarketBeat, the company has a consensus rating of “Hold”.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.